Peter de Keizer

Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA.

Samsara Therapeutics, Inc. operates as a biopharmaceutical platform company. It engages in the development and commercialization of first-in-class therapeutics for the treatment of unmet medical needs and age-related diseases. The company was founded by Sebastian Aguiar in 2018 and is headquartered in Lewes, DE.

GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA.

New York Academy of Sciences is an independent, not-for-profit organization, which engages in the advancement of scientific research, education, and policy. The company was founded in 1817 and is headquartered in New York, NY.

The Association of Clinical Research Professionals is a non-profit organization that provides over 50 online and in-person training programs for individual sale and institutional licensing. The non-profit company is based in Alexandria, VA and was founded by Lynn E. Regina. The company's courses cover good clinical practice (GCP) and specialized topics, including the anatomy of a protocol, hypothesis development, study design, subject safety, and data integrity risk considerations. The company also offers clinical trial insights research, a solution that combines market research capabilities with unprecedented access. With over 13,000 members, the organization represents, supports, and advocates for clinical research professionals.

Genesis Research LLC provides pharmaceuticals services. It offers medical, scientific writing, simulation, artificial intelligence, machine learning, and natural language processing. The company was founded by Steven R. Arikian and Frank A. Corvino in 2009 and is headquartered in Hoboken, NJ.

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.

coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany.

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

Munich Biotech AG manufactures pharmaceuticals. The private company is based in Neuried, Germany. The German company was founded by Michael Teifel.

AEterna Zentaris GmbH engages in biopharmaceutical research. It specializes in the fields of oncology and endocrinology. The company is headquartered in Frankfurt, Germany.

Cambrian Biopharma, Inc. operates as clinical-stage biopharmaceutical company. The company is headquartered in Brooklyn, NY.

Isterian Biotech, Inc. engages in the business of biotechnology services. The company is headquartered in Brooklyn, NY.

HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation.

Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland.

TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts.

Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA.

SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA.

GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California.

Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD.

ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA.

Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA.

Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE.